{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:05:27Z","timestamp":1780563927750,"version":"3.54.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"The Italian Ministry of Education and Research (MUR): Dipartimenti di Eccellenza"},{"name":"University of Milan\u201d and PNC \u201cHub Life \u00adScience- Diagnostica Avanzata","award":["PNC-E3-2022-23683266"],"award-info":[{"award-number":["PNC-E3-2022-23683266"]}]},{"name":"University of Milan\u201d and PNC \u201cHub Life \u00adScience- Diagnostica Avanzata","award":["C43C22001630001"],"award-info":[{"award-number":["C43C22001630001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.1093\/ibd\/izag020","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:42:15Z","timestamp":1769172135000},"page":"1201-1202","source":"Crossref","is-referenced-by-count":1,"title":["The long game in ulcerative colitis: mirikizumab\u2019s four-year outcomes"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-0109","authenticated-orcid":false,"given":"Daniele","family":"Noviello","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan , Milano,","place":["Italy"]},{"name":"Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8175","authenticated-orcid":false,"given":"Flavio","family":"Caprioli","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan , Milano,","place":["Italy"]},{"name":"Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026060404340221200_izag020-B1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as \u00adinduction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2026060404340221200_izag020-B2","article-title":"Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: final findings from the LUCENT-3 Open-Label Extension Study","author":"Clemow","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026060404340221200_izag020-B3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026060404340221200_izag020-B4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026060404340221200_izag020-B5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060404340221200_izag020-B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/apt.18158","article-title":"Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4\u2009years of follow-up in the SELECTION open-label long-term extension study","volume":"60","author":"Feagan","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060404340221200_izag020-B7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1201\/66992762\/izag020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1201\/66992762\/izag020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:34:09Z","timestamp":1780562049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/6\/1201\/8490664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag020","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,19]]}}}